erythematosus and sarcoidosis, and lipid storage disorders. The recovery phase of an acute infection (usually viral) or bone marrow regeneration postchemotherapy is commonly associated with monocytosis.
Once these etiologies have been ruled out, clonal hematopoietic disorders need to be considered. Firstly, chronic myeloid leukemia (CML) with the distinctive Philadelphia chromosome and the BCR-ABL1 fusion oncogene must be evaluated and excluded [17] . Rearrangement of the platelet-derived growth factor receptors A (PDGFRA) and B (PDGFRB) should then be evaluated and excluded. PDGFRA (chromosome 4q12) and PDGFRB (chromosome 5q31-q32) are type III receptor tyrosine kinases. Chromosomal translocations involving PDGFRA/B have been associated with myeloid neoplasms characterized by prominent eosinophilia and responsiveness to imatinib [18, 19] . At times, PDGFR rearranged myeloid neoplasms can present with monocytosis and BM dysplasia, but given their unique responsiveness to imatinib, these are no longer classified as CMML [20] . Patients presenting with a clinical phenotype of CMML with eosinophilia, should be assessed for the t(5;12)(q31-q32;p13), giving rise to the ETV6(TEL)-PDGFRB fusion oncogene [20] . The association between monocytosis and PDGFRA rearrangements is uncommon [21, 22] . Finally, the presence of bone marrow dysplasia in at least one hematopoietic lineage should be established. If myelodysplasia is absent or minimal, a diagnosis of CMML can still be made if additional criteria in Table I are met.
Flow cytometry
Peripheral blood flow cytometry is a recent measure that has been used to help diagnose CMML [23] . Human monocytes can be divided into three subsets: CD14 1 
/CD16
2 (classical), CD14 1 /CD16 1 (intermediate) and CD14 low /CD16 1 (nonclassical), with different gene expression profiles, chemokine receptor expressions and phagocytic 
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activities [23, 24] . The classical monocytes constitute majority of the human monocytes ($85%) in healthy conditions [24] . Compared to healthy donors and patients with reactive monocytosis, CMML patients demonstrate an increase in the fraction of classical monocytes (CD14 1 /CD16
2 ) [cutoff value 94%] [23] . In this study, the associated specificity and sensitivity values were reported at 95.1 and 91.9%, respectively. Importantly this repartition was noted to be independent of the CMML mutational status and this increment corrected in CMML patients that responded to hypomethylating agents (HMA) [23] . These findings do need further validation.
Histopathology and immunohistochemistry
There is no single finding pathognomonic of the diagnosis of CMML. Bone marrow biopsies are often hypercellular with granulocytic hyperplasia and dysplasia. Monocytic proliferation can be present, but is often difficult to appreciate and immunohistochemical studies that aid in the identification of monocytes and their precursors is recommended [25] . Almost 80% of patients will demonstrate micromegakaryocytes with abnormal nuclear contours and lobations, and 30% of patients can have an increase in BM reticulin fibrosis [25] . Twenty percent of patients can demonstrate nodules composed of mature plasmacytoid dendritic cells. The identification of promonocytes requires expertise and these cells are to be summated with blasts while estimating the blast count [26] . Promonocytes are described as monocytic precursors that have a delicately convoluted, folded or grooved nucleus with finely dispersed chromatin, a small indistinct or absent nucleolus, and finely granulated cytoplasm (Fig.  2 ) [26, 27] . On immunophenotyping the abnormal BM cells often express myelomonocytic antigens such as, CD13, CD33, with variable expression of CD14, CD68, and CD64. Markers of aberrant expression include CD2, CD15, CD56 or decreased expression of CD14, CD13, HLA-DR, CD64, or CD36. The presence of myeloblasts can be detected by expression of CD34. The most reliable markers on immunohistochemistry include CD68R and CD163. The monocytic cells are often positive for nonspecific esterases and lysozyme, while the granulocytic precursors are often positive for lysozyme and chloroacetate esterase. This process can help differentiate CMML from other MPN such as CML and aCML, where BM monocytosis is uncommon.
The diagnostic criteria for CMML place a heavy onus on the presence of PB monocytosis. As discussed, monocytosis is associated with a variety of reactive and clonal causes. Persistent reactive monocytosis with marrow dysplasia can wrongly be labelled as CMML. Similarly, CMML patients with progressive dysplasia or splenomegaly might develop peripheral blood cytopenias, and in spite of having monocytosis, fail to meet the diagnostic criteria for CMML. Patients with proliferative phase PMF can present with leukocytosis and monocytosis, thus fulfilling current WHO CMML diagnostic criteria [28] . Bone marrow monocytosis can be seen in patients with underlying dysplasia and while these patients may progress to CMML, at this point, BM monocytosis is not incorporated into the diagnostic algorithm.
Cytogenetic abnormalities in CMML
Clonal cytogenetic abnormalities are seen in $20-30% of CMML patients [7, [29] [30] [31] . Common alterations include; trisomy 8,-Y, abnormalities of chromosome 7 (monosomy 7 and del7q), trisomy 21, and complex karyotypes [30] . The Spanish cytogenetic risk stratification system categorizes patients in to three groups; high risk (trisomy 8, chromosome 7 abnormalities, or complex karyotype), intermediate risk (all chromosomal abnormalities, except for those in the high and low risk categories), and low risk (normal karyotype or -Y), with 5-year OS of 4, 26, and 35%, respectively [30] . Recently, in a large international study, 409 patients with CMML were analyzed for cytogenetic and molecular abnormalities [32] . Thirty percent displayed an abnormal karyotype; with common abnormalities being, 18 (23%), 2Y (20%), 27/7q-(14%), 20q-(8%), 121 (8%), and der(3q) (8%) [32] . 
Molecular abnormalities in CMML
There has been an exponential discovery of several molecular abnormalities in patients with CMML. These can broadly be divided into the following categories: (a) mutations in epigenetic control of transcription [5, [33] [34] [35] [36] [37] , such as histone modification (EZH2, ASXL1, UTX), DNA methylation (TET2, DNMT3A), or both (IDH1, IDH2); (b) mutations in the spliceosome machinery (SF3B1, SRSF2, U2AF1, ZRSR2) [7] ; (c) mutations in genes that regulate cell signaling (JAK2, KRAS, NRAS, CBL, and FLT3) [38] [39] [40] [41] [42] ; (d) mutations in transcription factors and nucleosome assembly (RUNX1, SETBP1) [39, 43, 44] ; and (e) mutations in DNA damage response genes, such as TP53 and PHF6 [45] . The relative frequency of these mutations in individuals with CMML is shown in Table II . Of these, mutations involving TET2 ($60%), SRSF2 ($50%), ASXL1 ($40%), and the RAS pathway ($30%) are most frequent, with only frameshift and nonsense ASXL1 mutations independently impacting OS [4, 5] .
The ASXL1 gene (chromosome 20q11) regulates chromatin by interacting with the polycomb-group repressive complex proteins (PRC1 and PRC2) [33] . In a seminal paper, Abdel-Wahab et al. demonstrated that ASXL1 mutations resulted in loss of PRC2-mediated H3K27 trimethylation [46] . In addition, Balasubramani et al. demonstrated that ASXL1 truncations conferred enhanced activity on the ASXL1-BAP1 (BRCA associated protein 1) complex [47] . This resulted in global erasure of H2AK119Ub and depletion of H327Kme3, promoting dysregulated transcription and oncogenesis.
The TET2 gene located on chromosome 4q24 is a member of the TET family of proteins [48] . TET2 has a dioxygenase enzymatic activity and converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine (5hmC). 5hmC, represents a new base in genomic DNA, which may have a specific effect on transcription [49, 50] . Although TET2 mutations are widely prevalent in CMML ($60%), they have not been shown to independently impact either OS or leukemia-free survival (LFS) [5] . In a recent study, the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations (ASXL1wt/TET2mut), had a favorable impact on OS [51] . The reason for this association is unclear. In MDS and younger patients with CMML (age <65 years), the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations, has been associated with response to hypomethylating agents (5-azacitidine and decitabine) [52, 53] .
Spliceosome component mutations (SRSF2, SF3B1, and U2AF1) affect premRNA splicing [7] . SRSF2 mutations are common in CMML ($50%) and are associated with increasing age, less pronounced anemia and a diploid karyotype [7] . Thus far, SRSF2 mutations have not demonstrated an independent prognostic impact on both, OS and LFS [5, 7, 54] . SF3B1 mutations have a high prevalence ($80%) in patients with MDS and ring sideroblasts (RS) [55] and can also be seen in patients with CMML and RS ($10%) [7] . These mutations do not influence either the OS or LFS [56, 57] . Similarly, U2AF1 mutations are seen in $10% of CMML patients and have thus far lacked an independent prognostic effect [58] .
Common signal pathway mutations in CMML include; JAK2V617F ($10-15%), RAS (KRAS and NRAS $20-30%), RUNX1 ($15%), and CBL ($10-20%) [5, 39] . RAS mutations are often associated with a MPN-like phenotype [59] . Although univariate analysis studies with RAS mutations have demonstrated inferior outcomes in CMML, these findings have not been substantiated in multivariable models [5, 29] . The CBL gene codes for an E3 ubiquitin ligase involved in degradation of activated receptor tyrosine kinases. RING finger domain (RFD) mutations of CBL are frequently associated with UPD11q (uniparental disomy) and have been reported in 10-20% of patients with CMML [5, 39] . RUNX1 is essential for normal hematopoiesis and mutations can be seen in $10-15% of patients with CMML [5, 39] . Although these mutations do not impact OS, there is a trend towards a higher risk for AML progression [60] .
The sequence of genetic events leading to the clinical phenotype of CMML remains under investigation. It is thought that the initial driver mutation is likely to be a mutation in TET2 or ASXL1. This assumption is based on the high frequency of these mutations ($40-60%) in CMML [61, 62] and results of single-cell tracking experiments [63] . Secondary mutations in the spliceosome machinery (such as in SRSF2) and cytokine signaling (NRAS or CBL) may allow a subset of these clones to progress, resulting in the typical phenotype associated with this disease [45, 64] .
Risk Stratification
Numerous prognostic models have been developed for CMML. In this regard, the value of Bournemouth, Lille, International Prognostic Scoring Systems (IPSS) and the revised-IPSSS is limited, as they were designed primarily for patients with MDS, excluding CMML patients with a MPN phenotype [2, 65] . Table III describes all the CMML specific prognostic systems. The MD Anderson prognostic system (MDAPS) is CMML specific and identified a hemoglobin (HB) level <12 g/dL, presence of PB IMC, absolute lymphocyte count (ALC) >2.5 3 10 9 /L and !10% BM blasts as independent predictors for inferior OS [29] . The MDAPS was subsequently applied to 212 CMML patients in the Dusseldorf registry [66] ; in a univariate analysis circulating IMC had no prognostic impact, while on multivariable analysis, elevated lactate dehydrogenase, BM blast count >10%, male gender, HB <12 g/dL, and ALC >2.5 3 10 9 /L were independently prognostic [66] .
The Global MDAPS (2008) was developed for patients with de novo MDS, secondary MDS and CMML (n 5 1,915) [67] . Independent prognostic factors included; older age, poor performance status, thrombocytopenia, anemia, increased BM blasts, leukocytosis (>20 3 10 9 /L), chromosome 7 or complex cytogenetic abnormalities, and a prior history of red blood cell transfusions [67] . This model identified 4 prognostic groups with median survivals of 54 (low), 25 (intermediate-1), 14 (intermediate-2), and 6 months (high), respectively [67] . The CMML-specific prognostic scoring system (CPSS) identified 4 variables as being prognostic for both OS and LFS; FAB and WHO CMML subtypes, red blood cell transfusion dependency, and the Spanish cytogenetic risk stratification system [8, 30] . One point was accorded for each variable, with the exception of high risk cytogenetics which earned 2 points, and four risk categories were determined: low (0 points), intermediate-1 (1), intermediate-2 (2-3), and high risk (4-5) [8] .
The discovery of gene mutations in CMML has resulted in the development of molecular prognostic models. A Mayo Clinic study /L and circulating IMC [68] . ASXL1 mutations did not impact either the OS or the LFS. The study resulted in the development of the Mayo prognostic model, with three risk categories, low (0 risk factor), intermediate (1 risk factor), and high (!2 risk factors), with median survivals of 32, 18.5, and 10 months, respectively [68] . The GFM demonstrated an adverse prognostic effect for ASXL1 mutations in 312 patients with CMML; additional risk factors on multivariable analysis included age >65 years, WBC >15 3 10 9 /L, platelet count <100 3 10 9 /L and HB <10 g/dL in females and <11 g/dL in males [5] . The GFM model assigns three adverse points for WBC >15 3 10 9 /L and two adverse points for each one of the remaining risk factors, resulting in a threetiered risk stratification; low (0-4 points), intermediate (5-7) and high (8) (9) (10) (11) (12) , with respective median survivals of 56, 27.4, and 9.2 months [5] . It should be noted that all nucleotide variations (missense, nonsense and frameshift) were regarded as ASXL1 mutations in the Mayo study [68] , whereas only nonsense and frameshift ASXL1 mutations were considered in the French study [5] .
To further clarify the prognostic relevance of ASXL1 mutations, an international collaborative cohort of 466 CMML patients was analyzed [32] . In univariate analysis, survival was adversely affected by ASXL1 (nonsense and frameshift) mutations. In multivariable analysis, ASXL1 mutations, AMC >10 3 10 Seven clinical prognostic models, not incorporating ASXL1 mutational status (IPSS, R-IPSS, MDAPS, Global MDAPS, Dusseldorf, CPSS, and Mayo model) were statistically compared in a large dataset of CMML patients (n 5 1832) [65] . All seven models were found to be valid with comparable performance, but were vulnerable to upstaging [65] .
Rates of leukemic transformation vary among different series of CMML patients reported in the literature. However, most studies quote an incidence of 15-20% [69] [70] [71] . In a recent study (n 5 274) of CMML patients followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13%) [16] . On multivariable analysis, risk factors for BT were presence of circulating blasts (HR 5.7; 95% CI 2.8-11.9) and female gender (HR 2.6; 95% CI 1.3-5.1); and the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6%) and better with allogeneic stem cell transplant (SCT) (14.3 vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P 5 0.03) [16] .
Risk Adapted Therapy
After its inclusion as a specific category of myeloid neoplasms in the 2008 WHO classification, treatment options for CMML have evolved. In the late 1990s, major treatment options consisted of chemotherapy such as etoposide, cytarabine, all-trans retinoic acid [72] [73] [74] , topotecan [75, 76] 9-nitro-campothecin (a novel topoisomerase inhibitor) [77] , and lonafarnib (farnesyltransferase inhibitor) [78] . Collectively, response rates in these trials were disappointing and therapy was associated with significant toxicities.
The United States Food and Drug Administration (FDA) approved two hypomethylating agents, 5-azacitidine and decitabine, for treatment of patients with MDS. Two pivotal randomized studies that established the efficacy and safety of these drugs included a total of 361 patients with MDS [79, 80] However, these studies only had 14 patients with CMML each, and the response rates for patients with CMML were not reported separately. Since the publication of these studies, several Phase II studies have reported the outcomes of patients with CMML who were treated with hypomethylating agents [6, 57, [81] [82] [83] [84] [85] [86] [87] . A complete list of the studies, including the dose and schedule of the drugs used, toxicities, response rates and survival are shown in Table IV . The overall response rate ranged from 25-70% ($30-40%), and median OS ranged from 12 to 37 months. Braun et al. showed that mutations in ASXL1, NRAS, KRAS, CBL, FLT3, and JAK2 genes, and hypermethylation of the promoter of the tumor suppressor gene-transcription-intermediary factor-1 gene (TIF1g) did not predict response or survival in 39 CMML patients treated with decitabine. However, lower CJUN and CMYB gene expression levels independently predicted improved OS. There was a trend towards higher response rate in patients with a TET2 mutation (when not associated with an ASXL1 mutation), although it did not reach statistical significance [81] . On multivariable analysis, Ades et al. showed that bone marrow blasts >10% and WBC >13 3 10 9 /L had a prognostic impact on OS among 76 patients treated with azacitidine [6] . Fianchi et al. showed that improved OS was associated with an absolute monocyte count <10 3 10 9 /L, and peripheral blood blasts <5% at the start of therapy with hypomethylating agents [83] .
Pleyer et al. conducted a matched-pair analysis of CMML patients treated with azacitidine (n 5 42) versus those who were treated with best supportive care (BSC, n 5 42) or with hydroxyurea (n 5 22). Although there was an improvement in median OS in the azacitidine arm (31 months) compared to BSC (17 months), these results were not statistically different (P 5 0.25), possibly due to the small sample size. Similarly, there was no difference in median OS between the azacitidine and hydroxyurea treatment arms (7.5 vs. 6.2 months, respectively, P 5 0.22).
A recent phase I clinical trial (n 5 20) has demonstrated safety and potential efficacy (35% MDS international working group (IWG) and spleen response) with ruxolitinib (JAK inhibitor), in patients with CMML [88] . Additionally, given the inherent, demonstrable, GM-CSF (granulocyte-macrophage colony stimulating factor) dependant pSTAT5 (phosphorylated Signal Transducer and Activator of Transcription 5) sensitivity in CMML patients, targeted anti-GM-CSF monoclonal antibody therapy is being developed (NCT02546284; http://www.clinicaltrials.gov) [89] .
Allogeneic stem cell transplantation
Allogeneic stem cell transplantation (HCT) remains the only curative option for patients with CMML. This modality is however fraught with complications including, acute and chronic graft versus host disease (GVHD), nonrelapse mortality and post-transplant disease relapse. There unfortunately exists no prospective data analyzing the risks and benefits for HCT in CMML. CMML patients in retrospective series have ranged from 8 to 513, with the median ages ranging from 50 to 56 years. The response rates in these studies have ranged from 17 to 50%, and treatment related mortality from 12 to 52% [90] [91] [92] [93] [94] [95] [96] [97] . Table V highlights the outcomes with allogeneic HCT for patients with CMML. The 10-year OS of 85 patients who underwent HSCT at Fred Hutchinson Cancer Center was 40%. A multivariable model identified increasing age, higher HCT comorbidity index and poor-risk cytogenetics to be associated with increased mortality and reduced relapse-free survival (RFS) [90] . The European Group for Blood and Marrow Transplantation reported a 4-year OS of 33% and a relapse free survival of 27% in 513 CMML patients that underwent allogeneic HCT [96] . Of note, in this study, 95 patients did have secondary AML. Engraftment was successful in 95%. Grades 2-4 acute GVHD occurred in 33% of the patients and chronic GVHD was reported in 24%. Patients transplanted in CR had lower probability for non-relapse death (P 5 0Á002) and longer relapse-free and OS (P 5 0Á001 and P 5 0Á005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P 5 0Á005) [96] . A recent application of the CPSS in the HCT setting assessed 209 adult patients from 2001 to 2012 with a median age of 57 years and followed for a median of 51 months. On multivariate analysis, CPSS score, Karnofsky performance status and graft source were significant predictors of OS. In general, for younger patients with higher risk disease and an acceptable co-morbidity index, allogeneic HCT is the preferred treatment modality [52] . With the advent of reduced intensity conditioning and alternate donor sources (haploidentical HCT and double umbilical cord blood units), an increasing number of patients have access to HCT. While reduced intensity conditioning is associated with lower nonrelapse mortality, disease relapse rates are higher in comparison to myeloablative regimens [98, 99] . Similar to MDS, cytoreductive therapy or HMA are often considered prior to HCT in patients with increased BM blasts (CMML-2) or prior to a reduced intensity conditioning [100] . A recent retrospective study (n 5 83) demonstrated prior therapy with hypomethylating agents followed by allogeneic HCT was associated with a lower cumulative incidence of relapse (22 versus 35%; P 5 0.03), without a significant increase in the 1-year transplant related mortality [101] . This finding needs prospective validation.
Recommendations: Hydroxyurea remains the cornerstone of therapy for patients with myeloproliferative features. Guidelines for supportive care measures such as the use of erythropoietin analogs for the treatment of anemia, prophylactic antibiotics for isolated neutropenia and iron chelation therapy for patients with a heavy transfusion burden are in general similar to patients with MDS, and data for their use specifically in patients with CMML do not exist. Standard induction chemotherapy should be considered for all eligible patients who develop blast transformation. Hypomethylating agents remain the most commonly used therapeutic intervention for patients with CMML. The presence of an elevated WBC count (>13 3 10 9 /L), palpable splenomegaly and increased bone marrow blast percentage (>10%) are all associated with a worse survival while on therapy with hypomethylating agents. Although several novel mutations (such as ASXL1, SETBP1) have been described to adversely affect survival of untreated CMML patients, their impact on patients undergoing therapy with hypomethylating agents is unclear at this time. Unfortunately, the response rates and survival following therapy is suboptimal, and therefore clinical trial participation is strongly encouraged.
The role of allogeneic stem cell transplant in CMML remains controversial. Similar to MDS, young patients with an adverse survival as determined by newer prognostic models incorporating molecular aberrations should be considered for HCT. Older patients with a high HCT comorbidity index do not benefit from SCT, and are best suited for clinical trials.
Conclusion
CMML, a myeloid neoplasm with features of MDS and MPN, often presents with PB monocytosis and has an inherent risk for transformation to AML. Clonal cytogenetic changes are seen in $30% of patients and the Mayo French Cytogenetic system effectively risk stratifies CMML patients based on cytogenetic abnormalities. Gene mutations are seen in >90% of patients, with common abnormalities involving; epigenetic regulators (TET2 $60% and ASXL1 $40%), spliceosome components (SRSF2 $50%) and cell signaling (RAS $30%, CBL $15%). Of these, only frame-shift and nonsense ASXL1 mutations have been shown to negatively impact OS. Lower risk, CMML patients that present with MPN-like features are effectively managed with hydroxyurea. Hypomethylating agents are associated with overall response rates of $30-40%, with complete remission rates of $15%. These responses are generally not sustained and survival after loss of response in these patients is often dismal. Allogeneic HCT remains the treatment of choice for younger patients with higher risk disease. Complications of HCT including, nonrelapse mortality, acute, and chronic graft versus host disease, limit generalized applicability of this treatment strategy. The development of CMML specific disease response criteria and clinical trials exploiting the genetic and epigenetic abnormalities in CMML, are important milestones to look forward to.
